Literature DB >> 2847230

Human breast cancer in vivo: H-1 and P-31 MR spectroscopy at 1.5 T.

P E Sijens1, H K Wijrdeman, M A Moerland, C J Bakker, J W Vermeulen, P R Luyten.   

Abstract

To assess the potential of in vivo magnetic resonance (MR) spectroscopy for breast cancer, hydrogen-1 and phosphorus-31 MR spectra of five malignant human breast tumors were compared with those of unaffected breast tissue. The water-to-fat ratio was high in the tumors (average, 2.2) but low in the unaffected tissue (average, 0.3). The P-31 spectrum of normal breast tissue showed low levels of phosphomonoesters (PMEs), inorganic phosphate, phosphodiesters (PDEs), and ATP. In addition, an intense phosphocreatine (PCr) signal was observed in breast tissue of young women: The relative intensities of the PCr and ATP signals had a mean value of 1.9. The tumor spectrum showed elevated levels of PMEs, Pi, and PDEs, while no PCr was seen (PCr/ATP less than 0.2). In two breast cancers treated with radiation therapy, resulting in a decrease of tumor volume of more than 50%, a similar change in the tumor P-31 spectrum was observed: An intense PCr signal developed (PCr/ATP = 1.1). Control experiments indicated that the appearance of PCr after radiation therapy was the result of a radiation-induced metabolic change in the tumor itself.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2847230     DOI: 10.1148/radiology.169.3.2847230

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  24 in total

Review 1.  Metabolite quantification and high-field MRS in breast cancer.

Authors:  Ihab S Haddadin; Adeka McIntosh; Sina Meisamy; Curt Corum; Angela L Styczynski Snyder; Nathaniel J Powell; Michael T Nelson; Douglas Yee; Michael Garwood; Patrick J Bolan
Journal:  NMR Biomed       Date:  2009-01       Impact factor: 4.044

2.  In vivo determination of human breast fat composition by ¹H magnetic resonance spectroscopy at 7 T.

Authors:  Ivan E Dimitrov; Deborah Douglas; Jimin Ren; Nadine B Smith; Andrew G Webb; A Dean Sherry; Craig R Malloy
Journal:  Magn Reson Med       Date:  2011-06-07       Impact factor: 4.668

Review 3.  In vivo 1H MRS in the assessment of the therapeutic response of breast cancer patients.

Authors:  Uma Sharma; Hyeon Man Baek; Min Ying Su; Naranamangalam R Jagannathan
Journal:  NMR Biomed       Date:  2011-01-28       Impact factor: 4.044

4.  Effect of radiotherapy and chemotherapy on composition of tumor membrane phospholipids.

Authors:  J C Street; J A Koutcher
Journal:  Lipids       Date:  1997-01       Impact factor: 1.880

Review 5.  Biochemical characterization of breast tumors by in vivo and in vitro magnetic resonance spectroscopy (MRS).

Authors:  Uma Sharma; Naranamangalam R Jagannathan
Journal:  Biophys Rev       Date:  2009-01-17

6.  Human in-vivo 31P MR spectroscopy of benign and malignant breast tumors.

Authors:  J M Park; J H Park
Journal:  Korean J Radiol       Date:  2001 Apr-Jun       Impact factor: 3.500

7.  Phosphorus-31 nuclear magnetic resonance in vivo spectroscopy of human liver during hepatitis A virus infection.

Authors:  Y Yamane; M Umeda; T O'uchi; T Mitsushima; K Nakata; S Nagataki
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

Review 8.  Metabolism of breast cancer cells as revealed by non-invasive magnetic resonance spectroscopy studies.

Authors:  O Kaplan; J S Cohen
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

9.  The emergence of diagnostic imaging technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical guidelines.

Authors:  Laura S Gold; Gregory Klein; Lauren Carr; Larry Kessler; Sean D Sullivan
Journal:  Cancer Imaging       Date:  2012-01-25       Impact factor: 3.909

Review 10.  Clinical application of magnetic resonance imaging in management of breast cancer patients receiving neoadjuvant chemotherapy.

Authors:  Jeon-Hor Chen; Min-Ying Su
Journal:  Biomed Res Int       Date:  2013-06-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.